In ₹ Crore except Per Share Latest Annual | TORNTPHARM FY26 | SUNPHARMA FY26 | JBCHEPHARM FY26 | MANKIND FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 77.05× | ◆ 38.70× | — | 48.46× | 43.58× +77% | |
| P/B | 9.48× | ◆ 5.29× | — | 5.60× | 5.45× +74% | |
| EV/EBITDA | 39.37× | ◆ 23.53× | — | 26.84× | 25.19× +56% | |
| Market Cap | ₹1.67L Cr | ₹4.44L Cr | — | ₹92,715 Cr | ₹2.68L Cr -38% | |
| Growth | ||||||
| Revenue CAGR 3Y | 13.27% | 10.03% | 9.61% | ◆ 17.73% | 10.03% +32% | |
| Revenue CAGR 5Y | 11.80% | 11.78% | ◆ 15.22% | — | 13.50% -13% | |
| Net Income CAGR 3Y | 19.75% | 10.57% | ◆ 20.06% | 13.96% | 13.96% +41% | |
| Revenue YoY (latest Q) | ◆ 54.85% | 10.46% | -4.77% | 12.89% | 10.46% +424% | |
| Net Income YoY (latest Q) | 3.28% | 26.53% | -30.42% | ◆ 29.12% | 26.53% -88% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 32.61% | 30.33% | 26.70% | 25.34% | 26.70% +22% | |
| Net Income Margin | 15.29% | ◆ 19.69% | 17.10% | 13.57% | 17.10% -11% | |
| Return on Common Equity | 12.30% | 13.69% | ◆ 17.06% | 11.55% | 13.69% -10% | |
| Return on Capital Employed | 9.56% | 17.17% | ◆ 21.13% | 12.66% | 17.17% -44% | |
| Return on Assets | 4.82% | 10.58% | ◆ 14.28% | 6.90% | 10.58% -54% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.84× | 0.05× | ◆ 0.00× | 0.38× | 0.05× +1580% | |
| Interest Coverage | 8.94× | 43.65× | ◆ 166.06× | 4.27× | 43.65× -80% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹13,980 Cr | ₹58,462 Cr | ₹4,148 Cr | ₹14,278 Cr | ₹14,278 Cr -2% | |
| Net Income | ₹2,138 Cr | ₹11,509 Cr | ₹709 Cr | ₹1,938 Cr | ₹1,938 Cr +10% | |
| Total Assets | ₹44,312 Cr | ₹1.09L Cr | ₹4,969 Cr | ₹28,080 Cr | ₹28,080 Cr +58% | |
| EPS | ₹63.92 | ₹47.8 | ₹45.16 | ₹46.35 | ₹46.35 +38% | |
| Book Value per Share | ₹519.56 | ₹349.6 | ₹258.98 | ₹401.19 | ₹349.6 +49% | |